Can Steroids Increase Hemoglobin?
Yes, steroids can increase hemoglobin levels, but the effect depends critically on the type of steroid and the underlying condition being treated.
Type of Steroid Matters
The term "steroids" encompasses different drug classes with distinct mechanisms:
Corticosteroids (Prednisone/Prednisolone)
Corticosteroids effectively increase hemoglobin in specific bone marrow failure conditions, particularly Diamond-Blackfan anemia, where 60-80% of patients respond with hemoglobin increases to ≥9 g/dL 1. The mechanism involves stimulation of erythropoiesis in abnormal bone marrow.
- In Diamond-Blackfan anemia, prednisone at 2 mg/kg/day produces reticulocytosis within 10-14 days and rising hemoglobin in responders 1
- Corticosteroids also show efficacy in myelofibrosis, with 40% of severely anemic patients achieving anemia response 2
- In hereditary spherocytosis hemolytic crises, steroid therapy increased hemoglobin in 74% of episodes (versus 25% without treatment, p=0.015) 3
However, corticosteroids do NOT increase hemoglobin in normal bone marrow. Studies of patients with acute lymphoblastic leukemia in remission showed no rise in hemoglobin or red blood cell count with prednisone pulses 4. The effect appears limited to conditions with abnormal erythropoiesis or hemolysis.
Androgenic/Anabolic Steroids (Testosterone)
Androgenic steroids consistently stimulate erythropoiesis and increase hemoglobin even in normal individuals, making polycythemia their most common adverse effect 5.
- Testosterone replacement therapy increases hematocrit by approximately 9.6% in healthy athletes 6
- In myelofibrosis patients, anabolic steroids produced favorable hemoglobin responses in 44% of cases 7
- The mechanism involves direct stimulation of erythropoietin-responsive cells and more primitive marrow precursors 8
- Blood donors on testosterone replacement therapy had mean hemoglobin of 173 g/L, with 25% of measurements ≥180 g/L 9
Clinical Algorithm for Predicting Hemoglobin Response
For corticosteroids:
- Bone marrow failure syndromes (Diamond-Blackfan anemia, aplastic anemia): High likelihood of response
- Hemolytic conditions with crisis: Moderate likelihood (dose ≥1 mg/kg/day for ≥1 week required) 3
- Myelofibrosis with anemia: 40% response rate 2
- Normal bone marrow/healthy individuals: No expected increase 4
For androgenic steroids:
- Nearly universal increase in hemoglobin/hematocrit regardless of baseline status
- Effect is dose-dependent and route-dependent (intramuscular preparations cause greater increases than transdermal) 5
Critical Caveats
The hemoglobin increase from androgenic steroids represents a significant cardiovascular risk, not a therapeutic benefit in most contexts. Testosterone-induced polycythemia (hematocrit >54%) requires dose reduction or therapeutic phlebotomy, as it increases risk of thrombotic events 9. Notably, repeat blood donation is often insufficient to maintain safe hematocrit levels in these patients 9.
For corticosteroid therapy in Diamond-Blackfan anemia, response requires adequate dosing (2 mg/kg/day initially) and duration (assess at 10-14 days), with doses <1 mg/kg/day or duration <1 week associated with treatment failure 1, 3.